
Current Price | $119.55 | Mkt Cap | $11.2B |
---|---|---|---|
Open | $117.32 | P/E Ratio | -11.59 |
Prev. Close | $119.55 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $117.27 - $119.80 | Volume | 838,200 |
52-Wk Range | $100.15 - $159.89 | Avg. Daily Vol. | 1,052,654 |
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.
Current Price | $119.55 | Mkt Cap | $11.2B |
---|---|---|---|
Open | $117.32 | P/E Ratio | -11.59 |
Prev. Close | $119.55 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $117.27 - $119.80 | Volume | 838,200 |
52-Wk Range | $100.15 - $159.89 | Avg. Daily Vol. | 1,052,654 |
The best Bull and Bear pitches based on recency and number of recommendations.
Strong revenue growth and a big pipeline make this a good long-term hold.
Short. Biopharma. Sells more stock than has revenues. Revs declining too.
Read the most recent pitches from players about SRPT.
Recs
Strong revenue growth and a big pipeline make this a good long-term hold.
Recs
srpt is the future of gene therapy in rare diseases. at the same time it is already strong today with very interesting pipeline and excellent management. momentum (post covid) + secular growt = sustainable growth and important gains. watch out but don't worry about volatility.
Recs
Potential to increase total addressable market from 13% to to 30% of Duchenne muscular dystrophy population by the end of 2020.
Find the members with the highest scoring picks in SRPT.
Newt805 (58.14) Score: +2,561.07
"It's one thing to feel that you're on the right path, but it's another to think that yours is the only path." Paulo Cuelho, novelist IX X XIII XIV XL XLIII
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
![]() |
Newt805 | 58.14 |
|
![]() |
5Y | $4.14 | +2,786.84% | +225.77% | +2,561.07 | 3 Comments |
ruben7086 | < 20 | 5/10/2012 |
![]() |
5Y | $4.80 | +2,390.62% | +215.62% | +2,175.00 | 0 Comment | |
rustam5 | 56.20 | 4/18/2012 |
![]() |
5Y | $5.40 | +2,113.89% | +210.49% | +1,903.40 | 0 Comment | |
embodiedheart | 28.71 | 4/2/2012 |
![]() |
5Y | $6.54 | +1,727.98% | +203.48% | +1,524.51 | 0 Comment | |
Apprentice15 | 86.20 | 2/8/2012 |
![]() |
3M | $6.54 | +1,727.98% | +219.05% | +1,508.93 | 0 Comment | |
blashmet | < 20 | 2/8/2012 |
![]() |
5Y | $6.78 | +1,663.27% | +219.88% | +1,443.39 | 0 Comment | |
benjaeger | 59.92 | 8/8/2011 |
![]() |
1Y | $6.90 | +1,632.61% | +268.99% | +1,363.62 | 0 Comment | |
Prof3215 | < 20 | 9/16/2011 |
![]() |
5Y | $7.50 | +1,494.00% | +255.67% | +1,238.33 | 1 Comment | |
TheMadFlea | < 20 | 3/22/2012 |
![]() |
5Y | $8.16 | +1,365.07% | +209.95% | +1,155.12 | 0 Comment | |
DudeTri | 42.57 | 6/13/2011 |
![]() |
5Y | $8.10 | +1,375.93% | +237.31% | +1,138.61 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.